Irradiation of regional nodes in breast cancer patients affects overall survival
the ONA take:
Irradiation of regional nodes in patients with stage I-III breast cancer has a minimal effect on overall survival, according to a recent study published in The New England Journal of Medicine; however, irradiation improved disease-free survival, distant-disease-free survival, and breast cancer mortality.
For the phase III trial, researchers enrolled 4,004 patients with positive axillary lymph nodes, or centrally or medially located primary tumors with negative lymph nodes. Patients were randomly assigned to receive whole-breast or thoracic-wall irradiation plus regional nodal irradiation or whole-breast or thoracic-wall irradiation alone.
Results showed that regional irradiation benefits patients with early stage breast cancer and acute adverse events associated with regional irradiation were modest.
However, the authors note that these results do not apply to patients with laterally located node-negative cancers, which represent the largest patient subgroup of early-stage breast cancers in first-world countries. The investigators plan to continue monitoring patients for a median follow-up of 20 years.
Irradiation of regional nodes in patients with stage I-III breast cancer has a minimal effect on overall survival.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|